U.S. approval of an expanded indication for transcatheter aortic valve replacement in patients without symptoms is among the ...
EW Investors with Losses Encouraged to Contact the Firm Before Dec. 13, 2024 DeadlineSan Francisco, California--(Newsfile Corp. - December 10, ...
At its investor day conference, Edwards Lifesciences Corp. prognosticated that an expanded indication in transcatheter aortic ...
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities ...
LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for ...
A Scottsdale hospital became the first non-clinical trial site in Arizona to perform a tricuspid heart valve replacement.
NYSE:EW) Edwards Lifesciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EW ...
Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...
Edwards enters 2025, its first full year as a purely structural heart company, in a strong position with major growth drivers in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter ...
Major Growth Drivers Transcatheter Aortic Valve Replacement (TAVR ... Surgical Therapies: Edwards plans to expand the adoption of its RESILIA portfolio, which includes innovative solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback